Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02230956 · ClinicalTrials.gov registry record · Phase 2
BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
NCT02230956 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 176 participants.
The verdict
NCT02230956, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of a single intra-articular injection of 2 doses of BOTOX® (onabotulinumtoxinA) compared with placebo as treatment for knee osteoarthritis symptoms.
Interventions
- DRUG Normal Saline
- BIOLOGICAL onabotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02230956
The ClinicalTrials.gov registry entry for NCT02230956 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal Saline is the first listed.
NCT02230956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02230956 about?
NCT02230956 is a clinical study titled "BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis". This study will evaluate the efficacy and safety of a single intra-articular injection of 2 doses of BOTOX® (onabotulinumtoxinA) compared with placebo as treatment for knee osteoarthritis symptoms.
What is the current status of trial NCT02230956?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2014-10. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02230956?
The interventions under investigation include: Normal Saline (DRUG), onabotulinumtoxinA (BIOLOGICAL).
Who is sponsoring clinical trial NCT02230956?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.